The study found no significant OS or PFS improvement with auto-HCT plus Rituxan versus Rituxan alone in MCL patients in first complete remission with undetectable MRD. Three-year OS rates were 82.1% ...

Late-breaking research reveals there is no benefit from high-dose chemotherapy followed by autologous stem cell transplant (ASCT) for patients with mantle cell lymphoma (MCL) in remission following ...

Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging survival. Patients are living years longer, thanks to novel combination therapies ...

Stem cell transplants remain essential for blood cancers, with expanded donor options including half-matched family members and umbilical cord blood. Cyclophosphamide has improved graft-versus-host ...

Please provide your email address to receive an email when new articles are posted on . Research has shown that autologous hematopoietic stem cell transplantation is an effective treatment for MS. At ...

It is the first evidence that MCL patients in complete remission, with undetectable minimal residual disease (MRD), may be able to rely on highly effective standard treatments and avoid the rigors of ...

Autologous stem cell transplant for patients with diffuse systemic sclerosis (SSc), without selecting for a particular hematopoietic cell type, performed about as well in a new single-arm trial as was ...

Hospitals are seeing success treating multiple myeloma with advanced therapies. Second autologous stem cell transplants, even ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed the last ...

Credit: Getty Images. The goal of HCT is to cure an underlying malignancy or hematologic disorder. The procedure can be performed in an inpatient or outpatient setting. Each setting is associated with ...